Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

Clinical Cancer Research

Volumn 12, Issue 1, 2006, Pages 144-151

  Siu, Lillian L ^a   Awada, Ahmad ^c   Takimoto, Chris H ^d   Piccart, Martine ^c   Schwartz, Brian ^e   Giannaris, Tom ^b   Lathia, Chetan ^e   Petrenciuc, Oana ^b   Moore, Malcolm J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Bayer Inc   (Canada)

^c JULES BORDET INSTITUTE   (Belgium)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; RAF PROTEIN; SORAFENIB; TRIACYLGLYCEROL LIPASE; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPIRATION PNEUMONIA; BLEEDING; BONE MARROW TOXICITY; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DEMOGRAPHY; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERABILITY; DRY SKIN; EDEMA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PANCREATIC NEOPLASMS; PYRIDINES;

EID: 31544460436     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1571     Document Type: Article

References (19)

1. Arteaga CL. Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? Clin Cancer Res 2003;9:1231-2.
2. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351:289-305.
3. Wilhelm SM, Carter C,Tang L, et al. BAY 43-9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
4. Gianpaolo-Ostravage C, Carter C, Hibner B. Antitumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models. Proc Am Assoc Cancer Res 2001;42:923.
5. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
6. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.
7. Moore M, Hirte H, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumours. Ann Oncol 2005;16:1688-94.
8. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61.
9. Vincent P, Zhang X, Chen CM, et al. Preclinical chemotherapy with the Raf kinase inhibitor BAY 43-9006 in combination with gefitinib, vinorelbine, gemcitabine or doxorubicin. Proc Am Assoc Cancer Res 2003;44:164.
10. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-52.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Richly H, Kupsch P, Passarge K, et al. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors. Proc Am Soc Clin Oncol 2004;22:207s.
13. Flaherty K, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol 2004;22:711s.
14. Sorafenib investigator's brochure, West Haven (Connecticut): Bayer Pharmaceuticals Corporation; 2004 September.
15. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal call carcinoma (RCC). Proc Am Soc Clin Oncol 2005;23:388s.
16. Flaherty KT, Redlinger M, Schuchter LM, et al. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2005;23:201s.
17. Siu LL, Winquist E, Agulnik M, et al. A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). Proc Am Soc Clin Oncol 2005;23:516s.
18. Escudier B, Szcylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005;23:380s.
19. Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 2005;15 Suppl 1:12-7.